Search Results

You are looking at 1 - 10 of 210 items for :

  • "Metastatic breast cancer" x
Clear All
Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar and Dorothy A. Shead

NCCN Guidelines Insights : Metastatic Breast Cancer, Version 1.2012 Version 1.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without

Full access

Ami M. Vyas, Hilary Aroke and Stephen Kogut

with metastases have a 5-year survival rate of only 26%, with almost none cured. 10 Despite advances in the management of HER2+ metastatic breast cancer (MBC), the response rate to first-line treatment is 50% to 80%, and 20% to 40% for second

Full access

Mary Cianfrocca and William J. Gradishar

treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women . J Clin Oncol 1998 ; 16 : 3439 – 3460 . 2. Carrick S Parker S Wilcken N . Single agent versus combination chemotherapy for

Full access

Gabrielle B. Rocque, Courtney P. Williams, Bradford E. Jackson, Stacey A. Ingram, Karian I. Halilova, Maria Pisu, Kelly M. Kenzik, Andres Azuero, Andres Forero and Smita Bhatia

. 7 – 10 Although these programs are showing early promise, few data exist about the outcomes for nonconcordant treatment regimens, particularly in metastatic breast cancer (MBC), in which treatment is heterogeneous and complex due to the large number

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia and Gabrielle B. Rocque

) include evidence-based, physician-recommended treatments. Concordance with NCCN Guidelines for Breast Cancer is increasingly recognized as a marker of high-quality cancer care. 1 , 2 Specifically in metastatic breast cancer (MBC), >45 guideline

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy and Cynthia X. Ma

Background It is estimated that >150,000 patients were living with metastatic breast cancer (MBC) in the United States in 2017. 1 Although progress in treatment strategies has led to significant improvement in overall survival in recent years, 1

Full access

William J. Gradishar

“There are lots of endocrine agents for treating hormone-positive metastatic breast cancer. For relapsed/refractory disease, the data do not support that one sequence is better than the other,” revealed William J. Gradishar, MD, Betsy Bramsen

Full access

Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley and Ben Ho Park

with estrogen receptor (ER)/progesterone receptor (PR)–negative, HER2-positive metastatic breast cancer who received trastuzumab and nab-paclitaxel in 2008 and experienced a complete remission (CR). Remarkably, she continues to have no evidence of

Full access

Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin and Harold J. Burstein

Background Advances in breast cancer treatment have significantly improved survival for patients with metastatic breast cancer (MBC) from 1 to 2 years in the 1970s to 1 to 3 years today. 1 - 3 However, MBC remains incurable, and the goals of

Full access

Priya Wanchoo, Chris Larrison, Carol Rosenberg, Naomi Ko, Cynthia Cantril, Naomi Moeller, Ruchit Parikh and Ana-Marija Djordjevic

multidisciplinary team care on cancer management . Pan Afr Med J 2011 ; 9 : 20 . 6. Mayer M Huñis A Oratz R . Living with metastatic breast cancer: a global patient survey . Commun Oncol 2010 ; 7 : 406 – 412 . 7. Palliative Care in